Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in...
June 20 2018 - 8:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company focused on
providing rapid systemic administration of therapeutics to subjects
using its proprietary Adhesive Dermally-Applied Microarray
(“ADAM™”) technology, today announces the recent publication of a
peer-reviewed paper regarding ADAM technology for the delivery of
zolmitriptan in the Journal of Pharmaceutics.
“Our in vitro study presents guidance on use of the appropriate
skin model to assess intracutaneous delivery of compounds using the
ADAM platform. This particular study, assessing the
intracutaneous delivery of zolmitriptan, is the first of its kind
and we are excited to present the results,” said Hayley Lewis,
senior vice president, operations at Zosano Pharma.
Data published in the Journal of Pharmaceutics evaluated how
different in vitro skin models influenced the absorption of
zolmitriptan with ADAM technology. This standardized method of
testing produced a model for evaluating the efficiency of
intracutaneous delivery of zolmitriptan. The model will be
helpful as Zosano continues to assess the efficiency of small
molecules delivered with ADAM.
About M207
M207 is our proprietary formulation of zolmitriptan delivered
utilizing Zosano's proprietary ADAM technology. Zosano's ADAM
technology consists of titanium microprojections coated with drug,
and in the case of M207, our formulation of zolmitriptan. The
drug-coated microneedles physically break through the stratum
corneum and penetrate into the epidermis and dermis, where
the dry drug coating is dissolved by the surrounding skin
interstitial fluid. In February 2017, the Company
announced statistically significant results from the ZOTRIP pivotal
study, which demonstrated that the 3.8mg dose of M207 met both
co-primary endpoints, achieving pain freedom and most bothersome
symptom freedom at 2 hours. In November 2017, the
Company announced the initiation of its long-term safety study
evaluating M207 and expects to file an NDA for M207 in the fourth
quarter of 2019.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical development milestones, sufficiency
of our capital resources and need for future funding and other
future events and expectations. Readers are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
Company's most recent annual report on Form 10-K. Although we
believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot in any way guarantee that the
future results, level of activity, performance or events and
circumstances reflected in forward-looking statements will be
achieved or occur. All forward-looking statements are based on
information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact: John Walker Chief Executive
Officer and Chairman of the Board 510-745-1200
Media Contact:Sara ZelkovicLifeSci Public
Relationssara@lifescipublicrelations.com212-916-2575
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Sep 2023 to Sep 2024